Identifying Treatments for Stage C2 Heart Failure

JAMA Cardiol. 2022 Jan 1;7(1):34-35. doi: 10.1001/jamacardio.2021.4024.

Authors

Clyde W Yancy^{1

2}, Adrian F Hernandez^{3

4}, Gregg C Fonarow^{5

6}

Affiliations

¹ Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Deputy Editor, JAMA Cardiology.
³ Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
⁴ Associate Editor, JAMA Cardiology.
⁵ Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
⁶ Section Editor, JAMA Cardiology.

PMID: 34643645
DOI: 10.1001/jamacardio.2021.4024

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cyclosporine
Heart Failure* / therapy
Humans

Substances

Cyclosporine